First VLP based vaccine for H1N1 (swine flu) in the world.

First recombinant trivalent seasonal influenza vaccine developed with VLP cell culture technology in the world.
Induces robust humoral response to all included strains-Antibody responses achieved are believed to be associated with reduced risk of influenza and its complications.
Provides seroprotection rates (≥70%) against all 3 strains Free from egg proteins safe in individuals with egg allergy Free from intact viral genome Non- infectious.